FDA Approves Nasonex For Use In Children As Young As Three
			MADISON, NJ -- December 2, 1999 -- Schering-Plough Corporation announced that Nasonex(R) (mometasone furoate monohydrate) Nasal Spray 50 mcg has received marketing approval from the U.S. Food and Drug Administration (FDA) for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in children as young as 3 years of age. Nasonex is the only drug in its class to be indicated for children as young as age three. Nasonex is currently marketed for the treatment of nasal symptoms of seasonal and perennial allergic rhinitis in adult and adolescent patients 12 years and older. It is also approved for the prevention of nasal symptoms of seasonal rhinitis in adult and adolescent patients 12 years and older, and is the only nasal inhaled steroid approved in the United States for this indication. A news report Doctor's Guide to Asthma Information and Resources   USA
Your comments

			Gatifloxacin Effective In Treatment Of Sinusitis
			Gatifloxacin has been shown to be equivalent to clarithromycin in the treatment of acute maxillary sinusitis. Doctor's Guide to Asthma Information and Resources   USA
Your comments

			In The News
			Various news articles including: Controversies in the Use of Inhaled Steroid Treatment for Allergic Rhinitis and Asthma (3/8/99) Possible pathogenic role of neutrophils in asthma (3/8/99) Allergic Disease Update - Part II (3/8/99) Cisapride (Propulsid) warning (2/25/99) Allergy Update Symposium - Part I (2/24/99) Newer prevention/treatment approaches for influenza (2/24/99) Breast Feeding of Allergic Infants (2/22/99) Prevalence of Nickel Sensitivity Increasing (1/22/99) American Academy of Allergy, Asthma and Immunology   USA
Your comments

			In The News - 1997 Archive
			Various news articles including: Prevalence, severity of asthma continue to rise in the elderly ABAI certification: its significance and importance to the medical community Cockroach allergen suspected as a contributing factor to the rise in asthma severity AAAAI Responds to New England Journal of Medicine Immunotherapy Study Study shows allergy shots help ragweed asthma sufferers Spirometry: An important component in the diagnosis and management of asthma Study reveals outcomes improved for asthmatics under specialty care Patients rate allergy/immunology favorably among specialists Study shows asthma specialists decrease long-run costs Recent allergy and health care issues in Washington, D.C. An update on aerosol therapy delivery devices The effect of wood smoke on asthmatics Recent study sheds new light on riddle of asthma U.S. emergency care for pediatric asthma differs from NIH guidelines Restaurants paying attention to food allergy lawsuits Managed care market requires responses Reducing indoor allergens American Academy of Allergy, Asthma and Immunology   USA
Your comments

			Lidocaine Improves Outcome Of Acute Asthma Attacks
			Researchers report that adding inhaled lidocaine to albuterol therapy improves pulmonary function in patients with acute asthma attacks. A news report Doctor's Guide to Asthma Information and Resources   USA
Your comments

	This icon indicates the target audience
	This grades the article - click to view the article
	This indicates an organization type - click for its details.
	Click to vote for this article

Primarily for:	Site Owner:	Content Rating:
Health Professionals Teens Kids	Professional Organization Commercial Organization Professional's Personal Site Layperson's site Layperson Organization	Position Statement Excellent Good Moderate Acceptable Poor No Grading Given
Symbol Explanation